Zacks Consensus Estimate This drug developer is expected to post quarterly loss of $0.85 per share in its upcoming report, which represents a year-over-year change of -174.2$15.67 million, up 56.7% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 1.17% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates ...